MANNKIND CORP Increase (Decrease) in Accounts and Other Receivables
MANNKIND CORP (MNKD) reported Increase (Decrease) in Accounts and Other Receivables of -$23.00 thousand for the 6-month period ending 2016-06-30, per its 10-Q/A filed 2016-08-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2018-02-27
- MANNKIND CORP increase (decrease) in accounts and other receivables for the quarter ending 2016-06-30 was -$144.00K, a 130.90% decline year-over-year.
- MANNKIND CORP increase (decrease) in accounts and other receivables for the quarter ending 2016-03-31 was $121.00K.
- MANNKIND CORP increase (decrease) in accounts and other receivables for the quarter ending 2015-12-31 was -$1.66M.
- MANNKIND CORP increase (decrease) in accounts and other receivables for the quarter ending 2015-09-30 was -$3.07M.
- MANNKIND CORP increase (decrease) in accounts and other receivables for fiscal 2015 was -$50.41M, a 199.95% decline from fiscal 2014.
- MANNKIND CORP increase (decrease) in accounts and other receivables for fiscal 2014 was $50.44M.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|
| 2016-06-30 | -$144.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2016-08-10 | -$23.00K 10-Q/A · filed 2016-08-10 | -$1.68M derived: sum of 3 quarters · filed 2018-02-27 | -$4.75M derived: sum of 4 quarters · filed 2018-02-27 |
| 2016-03-31 | $121.00K 10-Q · filed 2016-05-09 | -$1.53M derived: sum of 2 quarters · filed 2018-02-27 | -$4.60M derived: sum of 3 quarters · filed 2018-02-27 | -$4.14M derived: sum of 4 quarters · filed 2018-02-27 |
| 2015-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$4.72M derived: sum of 2 quarters · filed 2018-02-27 | -$4.26M derived: sum of 3 quarters · filed 2018-02-27 | -$50.41M 10-K · filed 2018-02-27 |
| 2015-09-30 | -$3.07M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2015-11-09 | -$2.60M derived: sum of 2 quarters · filed 2016-08-10 | -$48.76M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $466.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2016-08-10 | -$45.69M 10-Q/A · filed 2016-08-10 | ||
| 2015-03-31 | -$46.15M 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | $50.44M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |